NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$11.44

03 Oct
2023

0.260

OPEN

$11.03

2.33%

HIGH

$11.56

618,887

LOW

$11.03

TARGET
$17.50 53.0% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx 0.2 199.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 5.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 0.0% 0.0% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx0.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx14.6 M
Book Value Per Share xxxxxxxxxxxxxxx33.0
Net Operating Cash Flow xxxxxxxxxxxxxxx3.6 M
Net Profit Margin xxxxxxxxxxxxxxx1.26 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx0.46 %
Return on Invested Capital xxxxxxxxxxxxxxx0.46 %
Return on Assets xxxxxxxxxxxxxxx0.44 %
Return on Equity xxxxxxxxxxxxxxx0.46 %
Return on Total Capital xxxxxxxxxxxxxxx-3.95 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx3.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx-
Long Term Debt xxxxxxxxxxxxxxx-
Total Debt xxxxxxxxxxxxxxx-
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx40 M
Price To Book Value xxxxxxxxxxxxxxx24.08

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx16 M
Research & Development xxxxxxxxxxxxxxx13 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/09/2023

1

Buy

$17.50

52.97%

Neuren has reported its first profitable half-year result, Bell Potter notes. This follows the milestone payment for DAYBUE commercialisation and royalty income from sales by Acadia.

There are currently four Phase 2 trials underway for NNZ-2591 and Neuren has retained worldwide rights across these indications, the broker notes. Safety and tolerability has been demonstrated in Phase 1 studies.

The broker suggests the favourable deal structure with Acadia positions Neuren well for significant earnings growth. Target rises to $17.50 from $17.00, Buy retained.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of 199.00 cents.
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 60.60 cents.
Access Stockbroker Research History >

NEU STOCK CHART

FNArena News on NEU

1
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
2
Australian Broker Call *Extra* Edition – Sep 04, 2023

Sep 04 2023 - Daily Market Reports
3
FNArena Corporate Results Monitor – 01-09-2023

Sep 01 2023 - Australia
4
Rudi’s View: Low Expectations Not Low Enough?

Jul 19 2023 - Rudi's View
5
Australian Broker Call *Extra* Edition – Jul 17, 2023

Jul 17 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
2
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
3
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
4
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
5
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
6
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
7
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
8
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps
9
Dr Boreham’s Crucible: PolyNovo

Jul 06 2023 - Small Caps
10
CSL Disappoints But Brokers Retain The Faith

Jun 15 2023 - Australia